2023-06-26T11:53:17-05:00 2022-12-31 450250958 EIDE BAILLY LLP 5929 FASHION POINT DR STE 300 OGDEN UT 844034684 990 2022-01-01 831246927 CIVICA INC CIVI 8883040120 2912 W EXECUTIVE PKWY STE 325 LEHI UT 84043 EAMON FITZMAURICE CHIEF FINANCIAL OFFICER 8883040120 2023-06-26 1 EAMON FITZMAURICE 999009999 1 CHETT CAMPBELL CPA P01301037 8016211575 2023-06-26 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z NED MCCOY 2912 W EXECUTIVE PKWY STE 325 LEHI UT 84043 130877207 0 X WWW.CIVICARX.ORG X 2018 DE ALLEVIATE SUPPLY SHORTAGES FOR ESSENTIAL GENERIC MEDICATIONS AND ENSURE AFFORDABILITY FOR EVERYONE. 16 15 158 15 0 0 62213396 12653276 3891465 4527404 220056 42562 26047643 26730418 92372560 43953660 0 0 0 0 19608793 27547843 0 0 0 20947237 37617297 40556030 65165140 51816530 -21211480 199352322 233818442 104277014 159954614 95075308 73863828 X CIVICA'S MISSION IS TO ENHANCE AVAILABILITY AND AFFORDABILITY OF QUALITY GENERIC INJECTABLES FOR PATIENTS, ESPECIALLY HIGH NEEDS POPULATIONS, BY (1) ALLEVIATING DRUG SHORTAGES AND (2) PROVIDING THESE DRUGS AT A SUSTAINABLE AND AFFORDABLE LEVEL, BOTH VIA ITS MEMBER HOSPITAL SYSTEMS AS WELL AS NON-MEMBER ORGANIZATIONS INCLUDING NON-MEMBER COVERED ENTITIES LIKE 340B HOSPITALS AND ADDITIONALLY, GOVERNMENT ORGANIZATIONS INCLUDING VETERANS AFFAIRS AND DEPARTMENT OF DEFENSE. 0 0 34445123 31207902 GENERIC DRUG DISTRIBUTIONDEVELOP AN OPEN AND GROWING NETWORK OF HOSPITALS TO EXPAND THE REACH OF CIVICA'S MISSION AND ITS BENEFITS TO BOTH MEMBERS AND NON-MEMBERS. ALLEVIATE SHORTAGES OF ESSENTIAL DRUG PRODUCTS AND STABILIZE PRICING BY SECURING AVAILABILITY FROM EXISTING MANUFACTURERS FOR THE BENEFIT OF PATIENTS SERVED BY THESE MEMBERS AND NON-MEMBER CUSTOMERS. CIVICA'S MAJOR ACCOMPLISHMENTS TO DATE INCLUDE THE FOLLOWING:(1) CONTINUED CUSTOMER GROWTH WITH 43.7 MILLION PATIENTS SERVED TO DATE AND 18 ESSENTIAL MEDICINES LAUNCHED IN 2022. NEW CUSTOMERS ENROLLED INCLUDE NATIONWIDE NON-MEMBER 340B HOSPITALS THAT SERVE A DISPROPORTIONATE POPULATION OF HIGH-NEED PATIENTS, VETERANS AFFAIRS HOSPITALS, AND THE DEPARTMENT OF DEFENSE. DURING THE COVID-19 PANDEMIC, IN ADDITION TO SERVING THE NEEDS OF HOSPITAL SYSTEMS FOR 11 EMERGENCY MEDICATIONS. (2) CONTINUED LAUNCH OF ESSENTIAL MEDICINES DEEMED IN SHORT SUPPLY PER THE FDA OR ASHP DRUG SHORTAGES LISTS.(3) ESTABLISHED AND MAINTAINED APPROXIMATELY 6 MONTHS OF FINISHED GOODS INVENTORY TO BUFFER ANY SUPPLY CHAIN SHOCKS TYPICALLY EXPERIENCED IN THE INDUSTRY FOR ESSENTIAL STERILE INJECTABLE MEDICINES. (4) SINGLE TRANSPARENT AFFORDABLE PRICING TO ALL MEMBERS AND NON-MEMBERS REGARDLESS OF MEMBERSHIP STATUS, SIZE OF THE HOSPITAL, VOLUME OF DRUGS PURCHASED FROM CIVICA OR RELATIONSHIP LONGETIVITY WITH CIVICA. 16069282 FILL - FINISH FACILITYTHE COVID-19 PANDEMIC, WHICH RESULTED IN A SPIKE IN DEMAND FOR MEDICATIONS IN HOSPITALS MANAGING SIGNIFICANT PATIENT SURGES, BROUGHT TO LIGHT THE DEPENDENCE OF THE UNITED STATES ON FOREIGN MANUFACTURERS OF GENERIC, ESSENTIAL, LIFE-SAVING MEDICATIONS; ESPECIALLY STERILE INJECTABLES. IN AN EFFORT TO ON-SHORE END-TO-END MANUFACTURING OF SUCH STERILE INJECTABLES, AND AS A NATIONAL SECURITY MEASURE, BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY ("BARDA"), A U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES ("HHS") GOVERNMENT OFFICE RESPONSIBLE FOR THE PROCUREMENT AND DEVELOPMENT OF MEDICAL COUNTERMEASURES, PRINCIPALLY AGAINST BIOTERRORISM, INCLUDING CHEMICAL, BIOLOGICAL, RADIOLOGICAL AND NUCLEAR THREATS, AS WELL AS PANDEMIC INFLUENZA AND EMERGING DISEASES, AWARDED CONTRACT NO. 75A50120C00092 ("PRIME CONTRACT") TO PHLOW CORP., ("PHLOW") TO CREATE END-TO-END MANUFACTURING IN THE UNITED STATES. PHLOW IS A DELAWARE PUBLIC BENEFIT CORPORATION ENGAGED IN THE BUSINESS OF THE RESEARCH, DEVELOPMENT, AND COMMERCIALIZATION OF PHARMACEUTICAL PRODUCTS. PHLOW SUBCONTRACTED CERTAIN OF ITS OBLIGATIONS UNDER THE PRIME CONTRACT TO CIVICA WHEREBY CIVICA WILL QUALIFY, DESIGN, BUILD, EQUIP, OPERATE, AND OWN A 120,000 SQUARE FOOT, TWO-STORY, CGMP COMPLIANT ASEPTIC FILL-FINISH FACILITY ("FILL-FINISH FACILITY"), TO BE FUNDED, AT LEAST PARTIALLY, WITH $100,000,000 PROVIDED BY BARDA. THE FILL-FINISH FACILITY WILL BE CAPABLE OF, AMONG OTHER THINGS, PROVIDING AT LEAST 90 MILLION ASEPTIC OR TERMINALLY STERILIZED VIALS AND 50 MILLION PRE-FILLED SYRINGES ANNUALLY. DURING 2022, CIVICA COMPLETED SUBSTANTIAL CONSTRUCTION OF THE FACILITY AND EQUIPMENT DELIVERIES COMMENCED IN 2022. SUBMISSION OF THE APPLICATION FOR THE APPROVAL OF THE FACILITY, WITH THE FIRST PRODUCTS AND COMMENCEMENT OF COMMERCIAL PRODUCTION, ARE ANTICIPATED IN 2024. CIVICA INTENDS TO USE THE FILL-FINISH FACILITY TO, AMONG OTHER THINGS, (1) MANUFACTURE STERILE INJECTABLES IN FURTHERANCE OF ITS GENERIC DRUG DISTRIBUTION PROGRAM IDENTIFIED PREVIOUSLY, (2) SUPPORT THE NEEDS OF THE U.S. GOVERNMENT FOR ANY FUTURE PANDEMICS OR SIMILAR EMERGENCIES, (3) PROVIDE SURPLUS MANUFACTURING CAPACITY TO OTHER U.S.-BASED STERILE INJECTABLE MANUFACTURERS WHO SERVE THE NEEDS OF THE COUNTRY FOR SHORTAGE MEDICATIONS, AND (4) PRODUCE LOW-COST INSULIN FOR THE US MARKET TO ALLEVIATE DISTRESS THAT AFFORDABILITY CHALLENGES CAUSE TO PATIENTS. 3059592 49920 OUT-PATIENT SERVICESON OR ABOUT JANUARY 23, 2020, CIVICA ANNOUNCED AN ARRANGEMENT WITH THE BLUE CROSS BLUE SHIELD ASSOCIATION ("BCBSA") AND A NUMBER OF INDEPENDENT BLUE CROSS AND BLUE SHIELD COMPANIES ("BCBSS; WITH BCBSA, THE "BLUES"). THE ARRANGEMENT INVOLVED THE CREATION OF A NEW BUSINESS ENTITY, CIVICASCRIPT, DEDICATED TO LOWERING THE COST OF SELECT OUTPATIENT GENERIC MEDICATIONS IN RESPONSE TO THE IMPACT OF HIGH DRUG COSTS ON THE HEALTH OF AMERICANS AND THE OVERALL AFFORDABILITY OF HEALTH CARE BY DEVELOPING AND MANUFACTURING GENERIC OUTPATIENT MEDICATIONS. IN FURTHERANCE OF THE ARRANGEMENT, ON OR ABOUT JANUARY 27, 2020, CIVICA CAUSED CIVICASCRIPT TO BE ORGANIZED AS A DELAWARE LIMITED LIABILITY COMPANY TO PROMOTE PUBLIC BENEFITS, INCLUDING PROMOTION OF AVAILABILITY OF AFFORDABLE OUTPATIENT GENERIC DRUGS. CIVICASCRIPT, A STATUTORY PUBLIC BENEFIT LLC UNDER DELAWARE LAW, IS TREATED AS A CORPORATION FOR U.S. FEDERAL INCOME TAX PURPOSES.BASED ON MARKET AND OTHER RESEARCH BY CIVICASCRIPT, AS APPROVED BY ITS BOARD, CIVICASCRIPT IS CURRENTLY IN THE PROCESS OF DEVELOPING GENERIC VERSIONS OF CERTAIN MEDICATIONS. IN ALIGNMENT WITH CIVICASCRIPT'S FOUNDING MISSION, THESE GENERIC MEDICATIONS WILL BE SOLD TO CIVICA-AFFILIATED HOSPITALS, ALL "340B HOSPITALS,", ALL VETERANS AFFAIRS ("VA") HOSPITALS, AND TO RETAILERS.CIVICA, INC. ENTERED INTO A SERVICES AGREEMENT EFFECTIVE SEPTEMBER 1, 2020 WITH CIVICASCRIPT. CIVICA, INC. IS A MEMBER OF CIVICASCRIPT AND A RELATED PARTY. THE PROVISIONS OF THIS AGREEMENT ALLOW FOR CIVICA, INC. TO PROVIDE CIVICASCRIPT WITH ADMINISTRATIVE SUPPORT AND OTHER SERVICES TO ENABLE THE PUBLIC TO REALIZE THE BENEFITS CIVICASCRIPT INTENDS TO PROVIDE. THESE SERVICES INCLUDE EXECUTIVE MANAGEMENT SERVICES, PROFESSIONAL ASSISTANCE, RISK MANAGEMENT, QUALITY & REGULATORY SUPPORT AND OVERSIGHT, FINANCE & ACCOUNTING SERVICES, AND DATA ANALYTICS. 53573997 0 1 0 0 0 0 0 0 0 1 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 1 5 0 1 158 1 0 0 0 0 1 1 0 0 0 X 16 15 0 0 0 0 1 1 1 1 0 0 0 1 1 1 1 1 1 1 1 0 UT X JENNIFER SPALDING 8883040120 2912 W EXECUTIVE PARKWAY STE 325 LEHI UT 84043 X DAN LILJENQUIST CHAIR 1.00 2.00 X X 0 0 0 CARTER DREDGE DIRECTOR 1.00 X 0 0 0 LOUIS FIERENS DIRECTOR 1.00 2.00 X 0 0 0 DENNIS DAHLEN DIRECTOR 1.00 X 0 0 0 SHELLEY LYFORD DIRECTOR 1.00 2.00 X 0 0 0 MARTIN VANTRIESTE DIRECTOR AND PRESIDENT EMERITUS 1.00 2.00 X X 0 0 0 JAY WANT DIRECTOR 1.00 X 0 0 0 KATHLEEN SANFORD DIRECTOR 1.00 X 0 0 0 ANDREA NODA DIRECTOR 1.00 X 0 0 0 ERIN ASPREC DIRECTOR 1.00 X 0 0 0 WILLIAM RUTHERFORD DIRECTOR 1.00 X 0 0 0 JOANN ESCASA-HAIGH DIRECTOR 1.00 X 0 0 0 BLAKE WILKERSON DIRECTOR 1.00 X 0 0 0 MICHAEL ROWE DIRECTOR 1.00 X 0 0 0 DREW HOBBY DIRECTOR 1.00 X 0 0 0 NED MCCOY CHIEF EXECUTIVE OFFICER 24.00 16.00 X X 584866 389911 13932 JENNIFER SPALDING GENERAL COUNSEL 20.00 20.00 X 428358 428358 14286 EAMON FITZMAURICE CHIEF FINANCIAL OFFICER 24.00 16.00 X 249830 166553 197000 DEBBI FORD CHIEF COMMUNICATIONS 16.00 24.00 X 341477 512215 29791 RUSSELL ALAN GALL CHIEF MFG & SUPPLY CHAIN O 36.00 4.00 X 514310 57146 310958 DONNA GULBINSKI CHIEF QUALITY & REGULATORY 28.00 12.00 X 593278 254262 34830 KRISTOPHER WEIDLING CHIEF HUMAN RESOURCES 36.00 4.00 X 528395 58710 43959 STANFORD BENSON VP, PETERSBURG 40.00 X 465473 0 31291 3705987 1867155 676047 112 0 1 0 CRB BUILDERS LLC 701 EMERSON ROAD STE 500 ST LOUIS MO 63141 COMMERCIAL CONSTRUCTION 55789135 BUCHANAN INGERSOLL & ROONEY PC 501 GRANT STREET PITTSBURGH PA 15219 LEGAL SERVICES 1157949 MPP GROUP LLC 12250 CORPORATE PARKWAY MEQUON WI 53092 DRUG DEVELOPMENT SERVICES 397918 SARD VERBINNEN & CO LLC 900 THIRD AVENUE NEW YORK NY 10022 STRATEGIC COMMUNICATION CONSULTING 299559 UVU 175 SOUTH MAIN STREET SALT LAKE CITY UT 84111 RENT 273164 11 7552514 5100762 12653276 SERVICES TO CIVICASCRIPT 561499 4527404 4527404 4527404 42562 42562 113653965 86923547 26730418 26730418 43953660 31257822 0 42562 1346774 1103162 243612 22215804 18197291 4018513 447598 366634 80964 2449153 2006137 443016 1088514 891618 196896 447768 319426 128342 137738 98259 39479 3162206 2809055 353151 223748 223748 892931 713946 178985 1675269 1159676 515593 1095575 837893 257682 4784676 4784676 140931 99900 41031 1180783 878644 302139 SELLING EXPENSES 9149636 9149636 RESEARCH AND DEVELOPMEN 7271739 7271739 STARTUP COSTS 6824131 6824131 OTHER EXPENSE 630166 623102 7064 65165140 53573997 11591143 0 83398064 8158580 13112554 17746093 27819465 65109192 889726 693769 135949652 313751 73324354 135635901 808159 6474907 199352322 233818442 32372857 32851810 71904157 127102804 104277014 159954614 X -1305298 -26136172 96380606 100000000 95075308 73863828 199352322 233818442 -21211480 0 X 0 1 X 1 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 13117 9304 3813 758662 304447 454215 135177873 135177873 135635901 X PART X, LINE 2: THE ORGANIZATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX POSITIONS TAKEN AFFECTING ITS ANNUAL FILING REQUIREMENTS AND, AS SUCH, DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE CONSOLIDATED FINANCIAL STATEMENTS. THE ORGANIZATION WOULD RECOGNIZE FUTURE ACCRUED INTEREST AND PENALTIES RELATED TO UNRECOGNIZED TAX BENEFITS AND LIABILITIES IN INCOME TAX EXPENSE IF SUCH INTEREST AND PENALTIES ARE INCURRED. 1 X X X X X 0 1 0 0 0 0 0 1 0 NED MCCOY CHIEF EXECUTIVE OFFICER 303954 202636 280912 187275 0 0 7320 4880 2331 1554 594517 396345 0 0 DEBBI FORD CHIEF COMMUNICATIONS 154202 231303 187275 280912 0 0 4880 7320 7909 11864 354266 531399 0 0 RUSSELL ALAN GALL CHIEF MFG & SUPPLY CHAIN O 347218 38580 167092 18566 0 0 265256 29473 16570 1841 796136 88460 0 0 DONNA GULBINSKI CHIEF QUALITY & REGULATORY 265547 113806 327731 140456 0 0 8540 3660 17368 7444 619186 265366 0 0 JENNIFER SPALDING GENERAL COUNSEL 194265 194265 234093 234093 0 0 6100 6100 2134 2134 436592 436592 0 0 KRISTOPHER WEIDLING CHIEF HUMAN RESOURCES 338201 37578 190194 21132 0 0 10980 1220 30546 3394 569921 63324 0 0 EAMON FITZMAURICE CHIEF FINANCIAL OFFICER 229653 153102 20177 13451 0 0 106320 70880 13514 9009 369664 246442 0 0 STANFORD BENSON VP, PETERSBURG 264720 0 161750 0 39003 0 12200 0 21319 0 498992 0 0 0 PART I, LINE 4B EAMON FITZMAURICE - $165,000 RUSSELL GALL - $282,529 PART I, LINE 7 THERE ARE DISCRETIONARY BONUSES THAT ARE AWARDED DETERMINED BY THE COMPENSATION COMMITTEE. THE BONUSES ARE BASED UPON OVERALL BUSINESS ACCOMPLISHMENTS COMPARED TO THE GOALS SET BY THE ORGANIZATION. FORM 990, PART VI, SECTION A, LINE 6 CIVICA, INC. HAS THREE CLASSES OF MEMBERS AND EACH CLASS HAS DISTINCT RIGHTS AND PRIVILEGES. THE THREE CLASSES OF MEMBERS ARE GOVERNING MEMBERS, FOUNDING MEMBERS, AND PARTNERING MEMBERS. FORM 990, PART VI, SECTION A, LINE 7A EACH GOVERNING MEMBER HAS THE RIGHT TO NOMINATE ONE INDIVIDUAL TO SERVE ON CIVICA'S BOARD OF DIRECTORS. GOVERNING MEMBERS ALSO HAVE THE RIGHT TO DESIGNATE ONE INDIVIDUAL TO SERVE ON THE DRUG SELECTION ADVISORY COMMITTEE AND ONE TO SERVE ON THE MEDICAL TRENDS ADVISORY COMMITTEE. FOUNDING MEMBERS HAVE NO VOTING RIGHTS AS A MEMBER AS THOSE RIGHTS ARE ONLY CONFERRED UPON THE GOVERNING MEMBERS. HOWEVER, FOUNDING MEMBERS HAVE THE RIGHT TO DESIGNATE INDIVIDUALS TO SERVE ON THE TWO ADVISORY COMMITTEES DESCRIBED ABOVE. FORM 990, PART VI, SECTION A, LINE 7B THE GOVERNING DOCUMENTS REQUIRE THE APPROVAL OF TWO-THIRDS OF THE GOVERNING MEMBERS FOR THE: I) FORMATION OF AND DELEGATION OF ANY POWER BY THE BOARD OF DIRECTORS TO AN EXECUTIVE COMMITTEE OR ANY SIMILAR COMMITTEE; II) AMENDMENT OR RESTATEMENT OF THE ARTICLES OF INCORPORATIONS EXCEPT IN CERTAIN LIMITED CIRCUMSTANCES WHERE APPROVAL OF 100% OF THE GOVERNING MEMBERS IS REQUIRED, AND III) AMENDMENT OR RESTATEMENT OF THE BYLAWS. THE GOVERNING DOCUMENTS ALSO REQUIRE APPROVAL BY 90% OF ALL OF THE GOVERNING MEMBERS FOR I) CHANGING THE STRATEGIC LINES OF BUSINESS OF THE ORGANIZATION; II) DISPOSING OF ALL OR SUBSTANTIALLY ALL OF THE ORGANIZATION'S ASSETS; III) WINDING UP, DISSOLVING OR LIQUIDATING THE ORGANIZATION; IV) MERGING WITH ONE OR MORE OTHER ENTITIES; OR V) CONSOLIDATING WITH ONE OR MORE OTHER ENTITIES. IN ADDITION, THE GOVERNING DOCUMENTS ALSO REQUIRE APPROVAL BY 100% OF ALL OF THE GOVERNING MEMBERS FOR CERTAIN ACTIONS INCLUDING: I) CHANGING CERTAIN TERMS OF CREDIT AGREEMENTS; AND II) ALTERING CERTAIN TERMS OF MASTER MINIMUM VIABLE VOLUME AGREEMENTS TO BENEFIT ONE MEMBER. FORM 990, PART VI, SECTION A, LINE 8B THERE IS NO COMMITTEE WITH AUTHORITY TO ACT ON BEHALF OF THE GOVERNING BODY. FORM 990, PART VI, SECTION B, LINE 11B THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD OF DIRECTORS REVIEWS THE FORM 990 PRIOR TO FILING. CIVICA ALSO SENDS A COPY OF FORM 990 TO OTHER MEMBERS OF THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 12C DIRECTORS AND OFFICERS HAVE BEEN PROVIDED TRAINING ON THE CONFLICT OF INTEREST POLICY AND PROCESS, ARE SURVEYED FOR POSSIBLE CONFLICTS OF INTEREST, AND REQUIRED TO DISCLOSE POTENTIAL CONFLICTS ON AN ANNUAL BASIS. THE ANNUAL CONFLICT OF INTEREST DISCLOSURES ARE COLLECTED AND REVIEWED BY GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER. IF A CONFLICT IS IDENTIFIED, THE INDIVIDUAL WITH THE CONFLICT OF INTEREST WILL NOT PARTICIPATE IN THE DELIBERATIVE DISCUSSION OR VOTE ON THE TRANSACTION INVOLVED. FORM 990, PART VI, SECTION B, LINE 15 CIVICA CONDUCTED AN INDEPENDENT COMPENSATION BENCHMARKING STUDY IN DECEMBER 2022 TO ASSESS ITS CURRENT COMPENSATION STRUCTURE AND LEVELS AGAINST THE INDUSTRY PEERS. THE RESULTS WERE PRESENTED TO THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS WILL BE MADE AVAILABLE UPON REQUEST. THE FORM 990 IS AVAILABLE THROUGH THE IRS AND OTHER PUBLIC DISCLOSURE WEBSITES. FORM 990, PART VII: ALL EMPLOYEE COMPESATION IS PAID BY THE REPORTING ORGANIZATION. THE TOTAL COMPENSATION IS THEN ALLOCATED TO THE VARIOUS RELATED ENTITIES BASED UPON THE PERCENT OF TIME THE OFFICERS SPEND ON EACH OF THE ENTITIES. THE COMPENSATION REPORTED IN PART VII REFLECTS THESE ALLOCATIONS VERSUS THE W-2 REPORTING. CIVICA FOUNDATION 2912 W EXECUTIVE PARKWAY LEHI UT 84043 844514428 FUNDRAISING DE 501(C)(3) 10 CIVICA INC 1 CIVICA OUTPATIENT SUBSIDIARY LLC 2912 W EXECUTIVE PKWY STE 325 LEHI UT 84043 844777602 PHARMACEUTICALS UT N/A C 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 CIVICA FOUNDATION C 7552514 CASH PAID